Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of argenx in a research note issued on ...

Equities researchers at William Blair issued their Q4 2026 earnings estimates for argenx in a report released on Monday, ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

The Work and Pensions Secretary has announced plans to tighten the eligibility criteria for Personal Independence Payment ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

瘢痕性类天疱疮是一种罕见的自身免疫性水疱性疾病，临床表现为红斑斑块、水疱和糜烂，并伴有瘢痕愈合。眼部瘢痕性类天疱疮（OCP）是一种更为罕见的疾病，发病率仅为百万分之0.8。OCP的特征是结膜炎症、上皮下发疱和进行性瘢痕形成，可导致倒睫和角膜穿孔等严重并发症。早期诊断和及时的免疫抑制治疗对于防止不可逆损伤的发生至关重要。在 希腊雅典举办的第29届欧洲白内障与屈光外科医师学会冬季会议（ESCRS ...

After hours: 14 March at 18:55:07 GMT-4 Loading Chart for ARGX ...